|
11-Jan-2021
European Commission grants 3 NNZ-2591 Orphan designations
European Commission grants 3 NNZ-2591 Orphan designations
|
7-Dec-2020
Notification of investor briefing webinar
Notification of investor briefing webinar
|
7-Dec-2020
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591
Neuren receives notice of positive opinion on all three Orphan designation applications for NNZ-2591
|
19-Nov-2020
Approval received for final stage of NNZ-2591 clinical trial
Approval received for final stage of NNZ-2591 clinical trial
|
29-Oct-2020
Quarterly report and cash flow statement for Q3 2020
Quarterly report and cash flow statement for Q3 2020
|
29-Sep-2020
Neuren requests Orphan designations for NNZ-2591 in Europe
Neuren requests Orphan designations for NNZ-2591 in Europe
|
22-Sep-2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
|
26-Aug-2020
Half-year Shareholder Update
Half-year Shareholder Update
|
26-Aug-2020
Half Yearly Report and Accounts
Half Yearly Report and Accounts
|
18-Aug-2020
Corporate presentation, 18 August 2020
Corporate presentation, 18 August 2020
|